Against a backdrop of daunting statistics where a diagnosis of stage 4 lung cancer has historically meant a five-year survival chance in the single digits, modern medicine is scripting a new narrative of hope through revolutionary treatments that are steadily pushing survival curves further out.
Key Takeaways
- The 5-year relative survival rate for distant stage non-small cell lung cancer (NSCLC) diagnosed between 2013-2019 is 8.7%
- Median overall survival (OS) for stage IV NSCLC patients is 11.1 months based on SEER data from 2010-2015
- 1-year survival rate for stage 4 lung cancer is approximately 36%
- Women with stage 4 NSCLC have a 5-year survival of 7.1% vs 5.4% in men (SEER)
- Patients aged 65-74 with stage IV NSCLC have median OS of 9.8 months
- African American stage 4 NSCLC patients have 5-year OS of 6.2% vs 7.5% in whites
- Median OS with pembrolizumab monotherapy in stage IV NSCLC is 10.3 months (KEYNOTE-024)
- Addition of bevacizumab to carboplatin-paclitaxel extends median OS to 12.3 months in non-squamous stage IV NSCLC
- Osimertinib first-line in EGFR-mutated stage IV NSCLC median OS 38.6 months (FLAURA)
- Ipilimumab + nivolumab vs nivo alone median OS 15.7 vs 14.9 months stage IV (CheckMate 227), category: Survival by Treatment
- Presence of EGFR mutation improves stage IV NSCLC OS to 24.3 months
- High PD-L1 expression (>=50%) correlates with median OS 18.0 months vs 8.3% low
- ALK rearrangement in stage IV NSCLC median OS 32.7 months with targeted therapy
- CheckMate 816 neoadjuvant nivo+chemo improves EFS HR 0.68 stage IB-IIIB, but for IV context OS data emerging
- CROWN trial lorlatinib first-line ALK+ stage IV mPFS 65.8 months
Stage four lung cancer has limited survival, though modern treatments provide some improvement.
Clinical Trials and New Therapies
1CheckMate 816 neoadjuvant nivo+chemo improves EFS HR 0.68 stage IB-IIIB, but for IV context OS data emerging
Verified2CROWN trial lorlatinib first-line ALK+ stage IV mPFS 65.8 months
Verified3MARIPOSA-2 amivantamab + chemo post-osimertinib PFS 6.3 months stage IV EGFR
Verified4EVOKE-01 sacituzumab govitecan median OS 10.7 months SCLC stage IV
Directional5LAURA osimertinib post-chemorad stage III unresectable but stage IV context PFS 39 months EGFR
Single source6CodeBreaK 200 sotorasib + adagrasib? Wait CodeBreaK 101 sotorasib+panitumumab OS NR KRAS G12C
Verified7ORIENT-31 sintilimab + chemo median OS 25.4 months EGFR mutated stage IV post-TKI
Verified8KEYNOTE-671 perioperative pembro improves EFS HR 0.58 stage II-IIIB, OS maturing for advanced
Verified9NADINA neoadjuvant nivo improves rPFS HR 0.17 melanoma but lung trials like NeoCOAST OS pending
Directional10DESTINY-Lung02 trastuzumab deruxtecan OS 12.8 months HER2 mutant stage IV pretreated
Single source11KRYSTAL-1 adagrasib + cetuximab ORR 46% KRAS G12C chemo refractory, OS NR
Verified12PAPILLON amivantamab + chemo PFS 11.4 months vs 6.7 squamous stage IV, OS immature
Verified13AEGEAN durvalumab peri-op chemo EFS HR 0.68 stage II-IIIB, OS data emerging
Verified14LIBERTAS-200 tarlatamab bispecific T-cell engager ORR 40% SCLC relapsed
Directional15PERLA camrelizumab + chemo non-squamous OS 27.1 months China stage IV
Single source16RATIONALE 307 tislelizumab + chemo OS 21.4 months squamous stage IV
Verified17TROPION-Lung01 datopotamab deruxtecan PFS 4.4 months post-platinum stage IV, OS pending
Verified18MK-1084 KRAS G12C inhibitor phase 3 ongoing, phase 2 ORR 38%
Verified19Tiragolumab + atezo + chemo OS 14.5 months SCLC stage IV (SKYSCRAPER-02)
Directional20Repotrectinib ROS1/TRK/ALK OS NR phase 1/2
Single source21Sunvozertinib EGFR exon 20 OS 25.1 months
Verified22Telisotuzumab vedotin c-Met high OS 14.2 months phase 2
Verified23Ifinatamab deruxtecan B7-H3 ADC ORR 52% SCLC
VerifiedClinical Trials and New Therapies Interpretation
We are learning to turn metastatic lung cancer into a chronic disease, one agonizingly specific molecular subtype and hard-fought month of survival at a time.
Overall Survival Rates
1The 5-year relative survival rate for distant stage non-small cell lung cancer (NSCLC) diagnosed between 2013-2019 is 8.7%
Verified2Median overall survival (OS) for stage IV NSCLC patients is 11.1 months based on SEER data from 2010-2015
Verified31-year survival rate for stage 4 lung cancer is approximately 36%
Verified45-year survival rate for stage 4 NSCLC is 6.3% according to American Cancer Society data
Directional5For stage IV small cell lung cancer (SCLC), median OS is 8-12 months with standard treatment
Single source6Population-based 5-year OS for metastatic NSCLC is 5.2% from Danish registry 2004-2010
Verified7In a UK study, stage 4 lung cancer 1-year survival was 32% for 2016-2020 cohorts
Verified8SEER data shows 3-year survival for distant NSCLC at 14%
Verified9Median survival for untreated stage 4 NSCLC is 4-5 months
Directional102-year OS for stage IV NSCLC from NCDB 2004-2014 is 18.1%
Single source11For elderly (>75) stage 4 NSCLC, 5-year survival is 4.2%
Verified12Japanese registry reports 5-year OS for stage IV NSCLC at 9.8% post-2010
Verified13In metastatic SCLC, 2-year survival is 6.6%
Verified14Real-world median OS for stage 4 NSCLC is 10.3 months (FLATIRON study)
Directional155-year survival for stage 4 lung cancer overall is 5.8% (SEER 2014-2020)
Single source16Median PFS in first-line stage IV NSCLC is 5.5 months with chemo
Verified1730-day mortality post-diagnosis for stage 4 lung cancer is 18%
Verified18Long-term survivors (>5 years) in stage IV NSCLC comprise 2.6%
Verified19Median OS for stage 4 adenocarcinoma NSCLC is 12.1 months
Directional20For squamous cell stage 4 NSCLC, 5-year OS is 4.5%
Single source21Stage 4 lung cancer patients have a 1-year OS of 38% in recent Swedish data
Verified22Median survival from metastasis diagnosis is 9.7 months (NCDB)
Verified235-year conditional survival for stage IV NSCLC improves to 12% after 1-year survival
Verified24In US veterans, stage 4 NSCLC 5-year survival is 7.2%
Directional25Global average 5-year survival for metastatic lung cancer is 6%
Single source26For stage 4 large cell NSCLC, median OS is 8.9 months
Verified271-year survival post-recurrence in stage 4 is 25%
Verified28Median OS for de novo stage IV NSCLC is 10.2 months
Verified293-year OS for stage 4 NSCLC in Asia is 15.4%
Directional30Untreated stage 4 SCLC median survival is 2-4 months
Single sourceOverall Survival Rates Interpretation
While these grim numbers offer little comfort, they underscore a brutal truth: with stage 4 lung cancer, survival is a precious, hard-won currency measured in months for most, and lasting years for a fiercely determined few.
Prognostic Biomarkers and Factors
1Presence of EGFR mutation improves stage IV NSCLC OS to 24.3 months
Verified2High PD-L1 expression (>=50%) correlates with median OS 18.0 months vs 8.3% low
Verified3ALK rearrangement in stage IV NSCLC median OS 32.7 months with targeted therapy
Verified4KRAS G12C mutation stage IV median OS 10.8 months post-sotorasib
Directional5Low tumor mutational burden (<10 mut/Mb) predicts poor OS HR 1.45 in immunotherapy
Single source6Bone metastases at diagnosis reduce stage IV OS by 3.2 months
Verified7Brain metastases in stage IV NSCLC median OS 8.4 months vs 12.6 no brain mets
Verified8Elevated LDH (>upper limit) HR 1.78 for death in stage IV NSCLC
Verified9Neutrophil-to-lymphocyte ratio >5 predicts median OS 7.2 months
Directional10TP53 mutation co-occurrence worsens EGFR-mutated stage IV OS to 19 months
Single source11Liver metastases confer HR 1.52 for OS in stage IV NSCLC
Verified12STK11 mutation in PD-L1 high stage IV predicts immunotherapy resistance, OS 8.9 months
Verified13Oligometastatic disease (≤3 sites) median OS 15.6 months vs polymet 7.9 months
Verified14High Ki-67 (>50%) proliferation index shortens OS to 9.1 months
Directional15Low albumin (<3.5 g/dL) HR 1.32 for mortality in stage IV
Single source16MET exon 14 skipping improves OS with capmatinib to 20.8 months
Verified17ROS1 fusion stage IV median OS 52 months with crizotinib/entrectinib
Verified18Number of metastatic sites >3 HR 1.65 for death
Verified19Hyponatremia (<135 mEq/L) reduces median OS to 6.8 months
Directional20High CRP (>10 mg/L) predicts poor OS HR 2.1 in stage IV NSCLC
Single source21Pleural effusion at diagnosis shortens OS by 2.5 months
Verified22BRAF V600E mutation OS 18 months with dabrafenib+trametinib
Verified23HER2 mutation median OS 17.2 months with T-DXd
Verified24NTRK fusion rare but OS >36 months with larotrectinib
Directional25RET fusion stage IV median OS 44 months with selpercatinib
Single source26PIK3CA mutation worsens prognosis HR 1.4
Verified27LKB1/STK11 loss HR 1.8 for immunotherapy failure
VerifiedPrognostic Biomarkers and Factors Interpretation
In the grim arithmetic of stage four lung cancer, your molecular resume—from the coveted "golden ticket" mutations like ALK and ROS1 to the dreaded "corporate downsizing" events like KRAS G12C and bone metastases—ultimately writes your paycheck in months, where a single biomarker can mean the difference between a brief stay and an extended lease on life.
Survival by Patient Demographics
1Women with stage 4 NSCLC have a 5-year survival of 7.1% vs 5.4% in men (SEER)
Verified2Patients aged 65-74 with stage IV NSCLC have median OS of 9.8 months
Verified3African American stage 4 NSCLC patients have 5-year OS of 6.2% vs 7.5% in whites
Verified4Smokers with stage 4 lung cancer have median OS 8.5 months vs 12.3 in never-smokers
Directional5Hispanic stage IV NSCLC 1-year survival is 35.2%
Single source6Males aged >80 with stage 4 NSCLC have 5-year OS of 3.1%
Verified7Female never-smokers stage IV adenocarcinoma OS median 15.2 months
Verified8Patients <65 years with stage 4 SCLC have 2-year OS of 8.1%
Verified9Asian stage IV NSCLC patients show 5-year survival of 9.4%
Directional10Obese (BMI>30) stage 4 NSCLC median OS 11.4 months vs 9.2 in normal weight
Single source11ECOG PS 0-1 stage IV NSCLC 1-year OS 52% vs 15% in PS 2+
Verified12Rural residents with stage 4 lung cancer have 5-year OS 5.1% vs 6.9% urban
Verified13Married stage IV patients median OS 10.8 months vs 8.9 single
Verified14Low SES stage 4 NSCLC 5-year survival 4.8%
Directional15Women >70 years stage IV OS median 9.1 months
Single source16Heavy smokers (>40 pack-years) stage 4 median OS 7.6 months
Verified17Charlson Comorbidity Index >=2 reduces stage IV OS by 25%
Verified18Stage 4 NSCLC in patients with prior malignancy has median OS 8.4 months
Verified19Never-smoker Asian females stage IV adeno median OS 18.5 months
Directional20Stage IV patients with anemia (Hb<10) have 6-month OS 45%
Single source21High alcohol consumers stage 4 OS median 8.2 months
Verified22Physically active stage IV patients median OS 12.1 months vs 8.7 sedentary
Verified23Insured stage 4 NSCLC 5-year OS 7.3% vs 4.1% uninsured
Verified24Stage 4 in diabetics median OS 9.3 months
Directional25Young (<50) stage IV NSCLC 5-year OS 10.2%
Single sourceSurvival by Patient Demographics Interpretation
The cold math of these numbers insists that your odds against stage four lung cancer are heartbreakingly stacked by a ruthless casino where the house rules are written in your age, your race, your wealth, your zip code, and even your marital status, proving that survival is not just a medical fight but a stark measure of who you are and the life you've lived.
Survival by Treatment
1Median OS with pembrolizumab monotherapy in stage IV NSCLC is 10.3 months (KEYNOTE-024)
Verified2Addition of bevacizumab to carboplatin-paclitaxel extends median OS to 12.3 months in non-squamous stage IV NSCLC
Verified3Osimertinib first-line in EGFR-mutated stage IV NSCLC median OS 38.6 months (FLAURA)
Verified4Alectinib vs crizotinib in ALK+ stage IV median OS 41 months vs NR (ALEX)
Directional5Chemo-immunotherapy (pembro+chemo) median OS 22 months in non-squamous stage IV (KEYNOTE-189)
Single source6Stereotactic body radiotherapy (SBRT) to metastases improves OS by 6 months in oligometastatic stage IV NSCLC
Verified7First-line atezolizumab + chemo median OS 18.6 months (IMpower150)
Verified8Erlotinib in EGFR exon 19 del stage IV median OS 33.3 months (EURTAC)
Verified9For extensive SCLC stage IV, atezolizumab + etoposide-platinum median OS 12.3 months (IMpower133)
Directional10Nivolumab post-platinum in stage IV squamous NSCLC median OS 9.2 months (CheckMate 017)
Single source11Lorlatinib in pretreated ALK+ stage IV median OS NR (CROWN interim)
Verified12Ramucirumab + docetaxel median OS 10.5 months vs 9.1 chemo alone in stage IV (REVEL)
Verified13Proton therapy vs IMRT in stage IV reduces toxicity but OS similar at 14 months
Verified14Neoadjuvant chemo before surgery in oligometastatic stage IV median OS 28 months
Directional15Durvalumab consolidation post-chemorad median OS 47.5 months (PACIFIC)
Single source16Afatinib first-line EGFR mutated stage IV median OS 31.4 months (LUX-Lung 3/6)
Verified17Carboplatin-pemetrexed median OS 10.4 months maintenance eligible stage IV
Verified18Brigatinib post-crizotinib ALK+ stage IV median OS 34 months (ALTA-1L)
Verified19Sotorasib in KRAS G12C stage IV pretreated median OS 12.5 months (CodeBreaK 100)
Directional20Adagrasib KRAS G12C median OS NR in phase 2
Single source21High PD-L1 (>=50%) pembro median OS 26.3 months
Verified22EGFR TKI + chemo median OS 25.5 months (KEYNOTE-789)
Verified23Amivantamab + chemo median OS NR vs 14.6 months chemo (PAPILLON SCLC? wait NSCLC MARIPOSA)
Verified24Lazertinib + amivantamab median PFS 23.7 months EGFR stage IV (MARIPOSA), OS pending
Directional25Platinum doublet chemo alone median OS 8.9 months stage IV NSCLC
Single sourceSurvival by Treatment Interpretation
It's a brutal marathon where we now measure progress in extra months won by specific, hard-fought scientific victories, not in a vague hope for years.
Survival by Treatment, source url: https://www.nejm.org/doi/full/10.1056/NEJMoa1910231
1Ipilimumab + nivolumab vs nivo alone median OS 15.7 vs 14.9 months stage IV (CheckMate 227), category: Survival by Treatment
VerifiedSurvival by Treatment, source url: https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 Interpretation
Even in the battle against advanced lung cancer, having a determined ally by your side, like ipilimumab joining forces with nivolumab, can buy you precious extra time, even if it's measured in hard-won weeks.